Bisphosphonate therapy for prostate cancer
Bisphosphonate therapy is a systemic therapy that may be used in the treatment of prostate cancer to strengthen bone.
Bisphosphonate therapy may be used:
- to relieve bone pain or to prevent fractures in advanced hormone-refractory prostate cancer (palliative therapy)
- to prevent osteoporosis in men receiving hormonal therapy
Bisphosphonates are used in combination with other standard treatments for hormone-refractory prostate cancer.
The bisphosphonate used to treat hormone-refractory prostate cancer is:
- zoledronic acid (Zometa)
- Zoledronic acid is used to treat men who have little or no pain from bone metastases.
- This drug is effective in reducing the number of skeletal related events, including bone fractures and the need for radiation to bone metastases.
- This drug also reduces pain related to bone metastases.
- The drug has a number of side effects, and men should be informed of the risks and benefits of taking zoledronic acid.
Cancer information in over a hundred languages
The Canadian Cancer Society’s Cancer Information Service (CIS) is Canada’s only national, bilingual, toll-free service that offers personalized comprehensive cancer information in over 100 languages.